Developer docs
API playgroundTry for free, no card

Search company profiles

Sio Capital Management

Full company profile

uuid0005h1u

Namestring
Sio Capital Management
Legal namestring
Sio Capital Management, LLC
Websiteurl
siocapital.com
Company typeenum
Private
Founded yearint
2006
Descriptiontext

Sio Capital Management, LLC is a New York-based, SEC-registered investment advisor founded in 2006 by Dr. Michael Castor. The firm operates as a global equity market neutral healthcare hedge fund, taking long and short positions across healthcare equities spanning market caps, sub-sectors (biotech, specialty pharma, medtech, services, EU pharmaceuticals), and geographies. Its stated objective is to generate uncorrelated returns in both rising and falling markets through a combination of long stock selection and short selling against overvalued names with near-term negative catalysts. The fund is distributed exclusively to institutional investors via direct placement and a private login portal.

The firm's investment process is fundamentally-driven but augmented by proprietary quantitative tooling. The core proprietary system, "Qbert," is a quantitative screening model that ranks stocks on characteristics historically predictive of future out- or under-performance and is used as an idea-generation and research-prioritization engine. The firm supplements Qbert with internally maintained Dividend Discount Models (DDM), analyst comp sheets, and price target lists, and applies a team-based, peer-reviewed investment process. The investment team of six analysts and the founder/PM collectively hold credentials spanning medicine (MD), pharmacology (PhD), law (JD), statistics, computer science, and CFA designations, allowing the firm to underwrite clinical-trial, regulatory, and IP-driven catalysts that generalist funds typically cannot. Operations, compliance, marketing/trading, and accounting functions are run by a separate business team (CEO, COO, CCO, CFO-equivalent, Director of Marketing/Head of Trading, and operations staff), yielding a total headcount of roughly 12+.

Revenue is generated under traditional hedge fund economics — a recurring management fee (industry standard ~2% of AUM) plus a performance/incentive fee (~20% of net profits) — on a privately placed fund vehicle. Implied AUM derived from a single disclosed ~$24.53M position in Organon & Co. (representing ~4% of fund assets) suggests an asset base on the order of ~$600M, but exact AUM, returns, and fee terms are not publicly disclosed. The firm sells exclusively to institutional investors seeking healthcare-specific, market-neutral exposure and maintains no retail or public distribution channels.

Short descriptiontext

Sio Capital Management is a New York-based SEC-registered hedge fund founded in 2006 that runs a global equity market neutral long/short strategy exclusively in healthcare equities for institutional investors, using proprietary quantitative screening (Qbert) and fundamental research.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
healthcare hedge fund, equity market neutral, long-short equity, investment management, institutional asset management
Industry2 codes
1Equity Long/Short — Healthcare Focus
CodeFSAHAAAKPrimaryYes
2Market-Neutral Equity Long/Short
CodeFSAHAAADPrimaryNo
NAICS code1 code
  • Portfolio Management and Investment Advice523940
SIC code1 code
  • Investment Advice6282
Product category
Hedge Fund Management (Healthcare Equity)
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Investment Management (Hedge Fund)
TypeSubscription Recurring
Description

Sio Capital Management generates returns through a combination of capital growth and capital preservation by investing in healthcare equities. The fund takes both long and short positions in healthcare companies, with diversification across market cap, subsector, and investment thesis. Short investments deliver returns on their own merits and protect the portfolio during market downturns. Revenue is generated through traditional hedge fund economics, including management fees and performance/incentive fees.

siocapital.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Sio Capital Management runs a global equity market neutral healthcare hedge fund that takes both long and short positions in healthcare companies across market capitalizations and sub-sectors. The fund generates returns through prudent stock selection, proprietary quantitative screening (Qbert), and short positions designed to deliver uncorrelated performance and protect capital during market downturns. Capital is raised from institutional investors via private placement.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Sio Capital Healthcare Equity Market Neutral Hedge Fund
CategoryHedge Fund / Asset Management
Description

A global equity market neutral hedge fund that takes long and short positions in healthcare companies across market capitalizations, sub-sectors, and geographies. Designed for institutional investors seeking diversified, uncorrelated returns and downside protection through short positions during market downturns. Accessed via private placement and subscription agreements.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Baker Bros. Advisors
TypeDirect peer
Description

Biotech and life sciences-focused long/short fund founded in 2000. Directly comparable healthcare specialist with deep scientific research team and long-tenured analyst model similar to Sio.

TypeDirect peer
Description

Healthcare-focused long/short and long-only investment firm founded in 2001. Directly comparable to Sio due to dedicated healthcare focus, scientific research orientation, and public-equity market-neutral mandate.

TypeDirect peer
Description

Biotechnology-focused investment advisor running long/short public equity and private investments. Comparable to Sio through dedicated biotech/healthcare focus and science-driven fundamental research approach.

TypeDirect peer
Description

Healthcare-focused activist hedge fund investing in public healthcare equities. Comparable to Sio in dedicated healthcare specialization and fundamental long/short equity strategy with catalyst-driven theses.

TypeBroad incumbent
Description

Large, established healthcare investment firm spanning public equity, private equity, and royalty/structured finance. Comparable to Sio as a healthcare specialist but materially larger and more diversified across strategies.

TypeBroad incumbent
Description

Healthcare-focused investment firm with public equities, private investments, and structured financing capabilities. Comparable to Sio in healthcare specialization but with broader strategy portfolio and larger scale.

TypeBroad incumbent
Description

Large multi-strategy hedge fund platform that operates pod-style healthcare and equity long/short teams. Comparable to Sio in equity long/short execution but vastly larger and multi-sector.

TypeBroad incumbent
Description

Global multi-strategy hedge fund with significant equity market-neutral and sector-focused healthcare exposure. Comparable to Sio in market-neutral equity approach but operates at vastly greater scale across multiple sectors.

TypeBroad incumbent
Description

Multi-strategy hedge fund with discretionary long/short equity and sector-focused healthcare investing. Comparable to Sio in long/short equity execution but operates across multiple sectors with substantially larger AUM.

TypeDirect peer
Description

Healthcare-focused investment firm running both long/short public equity and life sciences venture strategies. Closely comparable to Sio given its dedicated healthcare specialization and biotech research depth.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment8 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sio Capital Management

Hedge Fund Management (Healthcare Equity)siocapital.com

Sio Capital Management is a New York-based SEC-registered hedge fund founded in 2006 that runs a global equity market neutral long/short strategy exclusively in healthcare equities for institutional investors, using proprietary quantitative screening (Qbert) and fundamental research.

What Sio Capital Management does

Sio Capital Management, LLC is a New York-based, SEC-registered investment advisor founded in 2006 by Dr. Michael Castor. The firm operates as a global equity market neutral healthcare hedge fund, taking long and short positions across healthcare equities spanning market caps, sub-sectors (biotech, specialty pharma, medtech, services, EU pharmaceuticals), and geographies. Its stated objective is to generate uncorrelated returns in both rising and falling markets through a combination of long stock selection and short selling against overvalued names with near-term negative catalysts. The fund is distributed exclusively to institutional investors via direct placement and a private login portal.

The firm's investment process is fundamentally-driven but augmented by proprietary quantitative tooling. The core proprietary system, "Qbert," is a quantitative screening model that ranks stocks on characteristics historically predictive of future out- or under-performance and is used as an idea-generation and research-prioritization engine. The firm supplements Qbert with internally maintained Dividend Discount Models (DDM), analyst comp sheets, and price target lists, and applies a team-based, peer-reviewed investment process. The investment team of six analysts and the founder/PM collectively hold credentials spanning medicine (MD), pharmacology (PhD), law (JD), statistics, computer science, and CFA designations, allowing the firm to underwrite clinical-trial, regulatory, and IP-driven catalysts that generalist funds typically cannot. Operations, compliance, marketing/trading, and accounting functions are run by a separate business team (CEO, COO, CCO, CFO-equivalent, Director of Marketing/Head of Trading, and operations staff), yielding a total headcount of roughly 12+.

Revenue is generated under traditional hedge fund economics — a recurring management fee (industry standard ~2% of AUM) plus a performance/incentive fee (~20% of net profits) — on a privately placed fund vehicle. Implied AUM derived from a single disclosed ~$24.53M position in Organon & Co. (representing ~4% of fund assets) suggests an asset base on the order of ~$600M, but exact AUM, returns, and fee terms are not publicly disclosed. The firm sells exclusively to institutional investors seeking healthcare-specific, market-neutral exposure and maintains no retail or public distribution channels.

Sio Capital Management firmographics

Firmographics
Name
Sio Capital Management
Legal name
Sio Capital Management, LLC
Website
https://siocapital.com
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
1–10 employees
Short description
Sio Capital Management is a New York-based SEC-registered hedge fund founded in 2006 that runs a global equity market neutral long/short strategy exclusively in healthcare equities for institutional investors, using proprietary quantitative screening (Qbert) and fundamental research.
Ownership category
akta.pro rank

Sio Capital Management industry classification

Industry
Product category
Hedge Fund Management (Healthcare Equity)
NAICS
Portfolio Management and Investment Advice (523940)
SIC
Investment Advice (6282)
akta.pro primary industry
Equity Long/Short — Healthcare Focus (FSAHAAAK)
akta.pro secondary industry
Market-Neutral Equity Long/Short (FSAHAAAD)

Keywords

  • Healthcare hedge fund
  • Equity market neutral
  • Long-short equity
  • Investment management
  • Institutional asset management

Where Sio Capital Management is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Sio Capital Management business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Investment Management (Hedge Fund): Sio Capital Management generates returns through a combination of capital growth and capital preservation by investing in healthcare equities. The fund takes both long and short positions in healthcare companies, with diversification across market cap, subsector, and investment thesis. Short investments deliver returns on their own merits and protect the portfolio during market downturns. Revenue is generated through traditional hedge fund economics, including management fees and performance/incentive fees.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Sio Capital Management product offering

Product offering

Core offering

Sio Capital Management runs a global equity market neutral healthcare hedge fund that takes both long and short positions in healthcare companies across market capitalizations and sub-sectors. The fund generates returns through prudent stock selection, proprietary quantitative screening (Qbert), and short positions designed to deliver uncorrelated performance and protect capital during market downturns. Capital is raised from institutional investors via private placement.

Differentiator

Problem solved

Functional benefit

Products and services

  • Sio Capital Healthcare Equity Market Neutral Hedge Fund A global equity market neutral hedge fund that takes long and short positions in healthcare companies across market capitalizations, sub-sectors, and geographies. Designed for institutional investors seeking diversified, uncorrelated returns and downside protection through short positions during market downturns. Accessed via private placement and subscription agreements.

Companies that use Sio Capital Management

Customer profile

Segments1 record

Ideal customer profiles1 record

Sio Capital Management technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Sio Capital Management partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Sio Capital Management competitors and assessment

Company assessment

Direct peers

  • Baker Bros. Advisors: Biotech and life sciences-focused long/short fund founded in 2000. Directly comparable healthcare specialist with deep scientific research team and long-tenured analyst model similar to Sio.
  • RA Capital Management: Healthcare-focused long/short and long-only investment firm founded in 2001. Directly comparable to Sio due to dedicated healthcare focus, scientific research orientation, and public-equity market-neutral mandate.
  • EcoR1 Capital: Biotechnology-focused investment advisor running long/short public equity and private investments. Comparable to Sio through dedicated biotech/healthcare focus and science-driven fundamental research approach.
  • Sarissa Capital Management: Healthcare-focused activist hedge fund investing in public healthcare equities. Comparable to Sio in dedicated healthcare specialization and fundamental long/short equity strategy with catalyst-driven theses.
  • Perceptive Advisors: Healthcare-focused investment firm running both long/short public equity and life sciences venture strategies. Closely comparable to Sio given its dedicated healthcare specialization and biotech research depth.

Broad incumbents

  • OrbiMed Advisors: Large, established healthcare investment firm spanning public equity, private equity, and royalty/structured finance. Comparable to Sio as a healthcare specialist but materially larger and more diversified across strategies.
  • Deerfield Management: Healthcare-focused investment firm with public equities, private investments, and structured financing capabilities. Comparable to Sio in healthcare specialization but with broader strategy portfolio and larger scale.
  • Millennium Management: Large multi-strategy hedge fund platform that operates pod-style healthcare and equity long/short teams. Comparable to Sio in equity long/short execution but vastly larger and multi-sector.
  • Citadel: Global multi-strategy hedge fund with significant equity market-neutral and sector-focused healthcare exposure. Comparable to Sio in market-neutral equity approach but operates at vastly greater scale across multiple sectors.
  • Point72 Asset Management: Multi-strategy hedge fund with discretionary long/short equity and sector-focused healthcare investing. Comparable to Sio in long/short equity execution but operates across multiple sectors with substantially larger AUM.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Sio Capital Management social profiles

Digital presence

Sio Capital Management financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sio Capital Management leadership team

Management profile

Number of profiles

Profiles14 records

Sio Capital Management funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sio Capital Management M&A and investment

M&A and investment

M&A

Investments8 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sio Capital Management

What does Sio Capital Management do?

Sio Capital Management runs a global equity market neutral healthcare hedge fund that takes both long and short positions in healthcare companies across market capitalizations and sub-sectors. The fund generates returns through prudent stock selection, proprietary quantitative screening (Qbert), and short positions designed to deliver uncorrelated performance and protect capital during market downturns. Capital is raised from institutional investors via private placement.

Is Sio Capital Management a public or private company?

Sio Capital Management is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Sio Capital Management founded?

Sio Capital Management was founded in 2006. It employs 1 to 10 people.

Where is Sio Capital Management based?

Sio Capital Management is headquartered in New York, United States, in the North America region.

How does Sio Capital Management make money?

One revenue line is on record: investment Management (Hedge Fund).

Who are Sio Capital Management's main competitors?

Direct peers on record are Baker Bros. Advisors, RA Capital Management, EcoR1 Capital, Sarissa Capital Management and Perceptive Advisors. Broad incumbents are OrbiMed Advisors, Deerfield Management, Millennium Management, Citadel and Point72 Asset Management.

Does Sio Capital Management have an API?

No public API is recorded for Sio Capital Management.

What industry is Sio Capital Management in?

Sio Capital Management's product category is Hedge Fund Management (Healthcare Equity). Its primary akta.pro industry code is FSAHAAAK, Equity Long/Short — Healthcare Focus, with a secondary code of FSAHAAAD, Market-Neutral Equity Long/Short. Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Motley FoolDoes This $25 Million Bet on a Stock Down 61% Signal Turnaround Potential at $6?Sio Capital Management disclosed a new investment in Organon, acquiring over 3.4 million shares worth approximately $24.53 million, as of February 17, 2026. Organon's shares are down about 61% over the past year, with recent financial challenges including declining revenue and profits, and a heavy debt load. Despite this, the company maintains a diversified portfolio and steady cash flow, but its stock is not currently considered a growth investment.QtimagingQT Imaging Announces $18 Million Private Placement Financing to Accelerate Growth – QT ImagingQT Imaging Holdings, Inc. announced an $18 million PIPE financing with anchoring from Sio Capital Management and participation from other institutional investors, expected to close on or before October 3, 2025. The company plans to use $5 million of proceeds to repay its senior secured term loan with Lynrock Lake Master Fund LP and deploy the remaining funds toward expanding U.S. and global go-to-market activities and the QTI Cloud Platform. QT Imaging's CEO called the financing an inflection point, adding that the company is preparing to relist on NASDAQ.YahooQT Imaging Announces $18 Million Private Placement Financing to Accelerate GrowthQT Imaging Holdings, Inc. announced it has entered into a securities purchase agreement for a PIPE financing expected to result in gross proceeds of approximately $18.0 million, with anchoring participation from Sio Capital Management and other institutional investors. The company plans to use $5.0 million of the proceeds to repay its senior secured term loan with Lynrock Lake Master Fund LP and deploy the remainder toward expanding U.S. and global go-to-market activities and the QTI Cloud Platform. QT Imaging also indicated it is making preparations to relist on the NASDAQ, having previously traded on the OTCQB market.AncoraheartAncora Heart Secures $80 Million in FinancingAncora Heart, Inc. announced the closing of an $80 million equity financing led by Sands Capital and Sio Capital to accelerate its pivotal CORCINCH-HF clinical study for the AccuCinch Ventricular Restoration System. The company also appointed Beverly Huss, former CEO of Pagonia Medical, to its Board of Directors to support upcoming FDA submissions and potential commercialization.BioSpaceAncora Heart Secures $80 Million in FinancingAncora Heart, Inc. announced the closing of an $80 million equity financing round on July 19, 2021. The funds were raised from Sands Capital, Sio Capital, and an undisclosed strategic investor, joining existing investors. The capital will be used to accelerate the CORCINCH-HF pivotal clinical study for its AccuCinch Ventricular Restoration System, a device designed to treat heart failure with reduced ejection fraction.PR NewswireMedicus Sciences Acquisition Corp. Announces Pricing of $80,000,000 Initial Public OfferingMedicus Sciences Acquisition Corp. announced the pricing of its $80 million initial public offering of 8 million units at $10 per unit on the Nasdaq Capital Market, expected to close on February 18, 2021. The blank check company, incorporated in the Cayman Islands and sponsored by an affiliate of Altium Capital Management and Sio Capital Management, two healthcare-focused investment funds with over $1 billion in combined assets, intends to use proceeds for business combinations in the healthcare and medical technology sectors. Maxim Group LLC is acting as sole book-running manager for the offering.